Pages that link to "Q58924276"
Jump to navigation
Jump to search
The following pages link to Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi (Q58924276):
Displaying 12 items.
- Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers (Q33420273) (← links)
- Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. (Q38368587) (← links)
- Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. (Q38466376) (← links)
- Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma (Q38557033) (← links)
- Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update (Q38642648) (← links)
- High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant (Q41525624) (← links)
- Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. (Q52777496) (← links)
- Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. (Q52779365) (← links)
- Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. (Q52895479) (← links)
- B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). (Q53174548) (← links)
- Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party (Q57796234) (← links)
- Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT (Q100526138) (← links)